SNSE Logo

Sensei Biotherapeutics, Inc. (SNSE) 

NASDAQ
Market Cap
$13.2M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
723 of 776
Rank in Industry
396 of 433

Largest Insider Buys in Sector

SNSE Stock Price History Chart

SNSE Stock Performance

About Sensei Biotherapeutics, Inc.

Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor …

Insider Activity of Sensei Biotherapeutics, Inc.

Over the last 12 months, insiders at Sensei Biotherapeutics, Inc. have bought $0 and sold $0 worth of Sensei Biotherapeutics, Inc. stock.

On average, over the past 5 years, insiders at Sensei Biotherapeutics, Inc. have bought $2.75M and sold $1.1M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 500 shares for transaction amount of $425 was made by Celebi John (President and CEO) on 2023‑09‑11.

List of Insider Buy and Sell Transactions, Sensei Biotherapeutics, Inc.

2023-09-11PurchasePresident and CEO
500
0.002%
$0.85$425-6.91%
2023-06-01Sale10 percent owner
955,738
3.3509%
$1.58$1.51M-40.07%
2023-02-23Purchase10 percent owner
2,200
0.0071%
$1.61$3,539-36.42%
2022-03-02Purchase
1,203
0.0037%
$3.20$3,850-49.40%
2022-03-02Purchase10 percent owner
1,203
0.0037%
$3.20$3,850-49.40%
2022-03-01Purchase
2,458
0.0082%
$3.60$8,849-51.84%
2022-03-01Purchase10 percent owner
2,458
0.0082%
$3.60$8,849-51.84%
2022-02-28Purchase
42
0.0001%
$3.60$151-52.91%
2022-02-28Purchase10 percent owner
42
0.0001%
$3.60$151-52.91%
2022-02-25Purchase
2,500
0.0079%
$3.65$9,125-54.39%
2022-02-25Purchase10 percent owner
2,500
0.0079%
$3.65$9,125-54.39%
2022-02-24Purchase
15,000
0.0483%
$3.63$54,450-53.26%
2022-02-24Purchase10 percent owner
15,000
0.0483%
$3.63$54,450-53.26%
2022-02-23Purchase
2,500
0.0082%
$3.80$9,500-54.09%
2022-02-23Purchase10 percent owner
2,500
0.0082%
$3.80$9,500-54.09%
2022-02-18Purchase
15,000
0.0473%
$3.97$59,550-56.93%
2022-02-18Purchase10 percent owner
15,000
0.0473%
$3.97$59,550-56.93%
2022-02-17Purchase
4,949
0.0164%
$4.17$20,637-56.69%
2022-02-17Purchase10 percent owner
4,949
0.0164%
$4.17$20,637-56.69%
2022-02-16Purchase
2,551
0.0083%
$4.25$10,842-57.85%

Insider Historical Profitability

<0.0001%
Cambrian BioPharma Inc10 percent owner
5231488
20.8002%
$0.52590<0.0001%
Peyer James
5231488
20.8002%
$0.52590<0.0001%
RICKS THOMAS Gdirector
341769
1.3589%
$0.5220<0.0001%
Celebi JohnPresident and CEO
111311
0.4426%
$0.5210
Apeiron Investment Group Ltd.10 percent owner
0
0%
$0.5211<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Newtyn Management$976,741.003.71930,230-40.83%-$673,882.310.21
The Vanguard Group$602,536.002.29573,844+0.03%+$202.65<0.0001
Renaissance Technologies$222,000.000.84211,000+47.03%+$71,010.54<0.0001
Geode Capital Management$143,165.000.54136,3180%+$0<0.0001
Bridgeway Capital Management$118,545.000.45112,9000%+$0<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.